Dxcover is developing a multi-cancer diagnostic platform that utilizes liquid biopsy and an AI engine for the early detection of brain tumors. This technology aims to improve patient survival rates by enabling earlier diagnosis, addressing the critical challenge of late-stage cancer detection.
Funding
$15.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Late-stage cancer detection significantly reduces patient survival rates, highlighting the critical need for earlier diagnostic methods. Traditional diagnostic approaches often focus solely on tumor markers, potentially missing early-stage signals and limiting the scope of analysis.
Solution
Dxcover is developing the PANAROMIC Platform, a multi-cancer diagnostic tool that utilizes liquid biopsies and artificial intelligence to improve early cancer detection. The platform employs a multi-omic approach, analyzing a broad spectrum of signals from blood samples beyond just tumor DNA to enhance the detection of early-stage cancers. The Dxcover platform combines novel hardware with proprietary AI algorithms to analyze patient blood samples and detect the presence or absence of disease. The platform's methodology is designed for deployment at various points in the diagnostic pathway, accommodating multiple diseases and requiring only a small sample volume with results available the same day.
Target Audience
The primary target audience includes clinicians dedicated to accurate early diagnosis, health services seeking cost-effective solutions, and biopharmaceutical companies looking for diagnostic partners.
Features
- Multi-omic spectral analysis of biofluids using infrared spectroscopy and machine learning
- Analyzes both tumor-derived and non-tumor signals
- Requires only 9 microliters of sample
- Provides results within the same day of sample receipt
- Compatible with a range of biofluids and disease applications
- Patented for the detection of multiple solid tumors in the US, EU, and China
- DROP DRY DETECT: Automated analysis and disease prediction powered by unique algorithms